Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Molecular Interactions between Mitochondrial Ferroptosis and Apoptosis Pathways in Acute Myeloid Leukemia

Kazuharu Kamachi, Hiroki Akiyama, Ran Zhao, Liang Zhang, Saurabh Kumar Gupta, Lauren B. Ostermann, Yuji Otsuki, Osamu Nagano, Hideyuki Saya, Ayumu Taguchi, Michael Andreeff, Jo Ishizawa

Blood (2024) 144 (Supplement 1): 2765.

https://doi.org/10.1182/blood-2024-201661

Published: 2024

Journal Articles

Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells

Yuki Nishida, Hideaki Mizuno, Edward Ayoub, Eiji Sugihara, Lauren B. Ostermann, Shayaun Khazaei, Darah Scruggs, Po Yee Mak, Baozhen Ke, Bing Z. Carter, Abhishek Maiti, Liandong Ma, Michael Andreeff

Blood (2024) 144 (Supplement 1): 2755.

https://doi.org/10.1182/blood-2024-207812

Published: 2024

Journal Articles

Reactivation of p53 in TP53 -Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Xiaogang Wu, Steffen Boettcher, Lauren B. Ostermann, Andrea Bedoy, Georgina Gener-Ricos, Jayastu Senapati, Courtney D. DiNardo, Anna Puzio-Kuter, Arnold Levine, Michael Andreeff

Blood (2024) 144 (Supplement 1): 4155.

https://doi.org/10.1182/blood-2024-208403

Published: 2024

Journal Articles

Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms

Rasoul Pourebrahim, Dexin Yang, Priyanka Khanna, Muharrem Muftuoglu, Lauren B. Ostermann, Shayaun Khazaei, Ran Zhao, Mihai Gagea, Simona Colla, Guillermo Garcia-Manero, Ruoyan Li, Michael Andreeff, Koichi Takahashi

Blood (2024) 144 (Supplement 1): 882.

https://doi.org/10.1182/blood-2024-207582

Published: 2024

Journal Articles

Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors

Rasoul Pourebrahim, Priyanka Khanna, Dexin Yang, Muharrem Muftuoglu, Lauren B. Ostermann, Shayaun Khazaei, Ran Zhao, Amma Asare, Richard A. Hajek, Sanghoon Lee, Sara Corvingo, Mihai Gagea, Anil Sood, Ruoyan Li, Koichi Takahashi, Michael Andreeff

Blood (2024) 144 (Supplement 1): 726.

https://doi.org/10.1182/blood-2024-208373

Published: 2024

Journal Articles

Calibrated Release IL15 Bivalent CD33 and/or FLT3 and NOT Emcn Logic Gated Gene Circuit CAR-NK Cell Therapy (SENTI-202) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models

Muharrem Muftuoglu, Mahesh Basyal, Li Li, Jiangxing Lv, Lauren B. Ostermann, Ran Zhao, Baozhen Ke, Hiroki Akiyama, Po Yee Mak, Bing Z. Carter, Han Deng, Yongshuai Li, Brian S. Garrison, Kanya L. Rajangam, Michael Andreeff

Blood (2023) 142 (Supplement 1): 4831.

https://doi.org/10.1182/blood-2023-191127

Published: 2023

Journal Articles

Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Yuki Nishida, Steffen Boettcher, Andrea Bedoy, Lauren B. Ostermann, Courtney D. DiNardo, Anna Puzio-Kuter, Arnold Levine, Michael Andreeff

Blood (2023) 142 (Supplement 1): 2261.

https://doi.org/10.1182/blood-2023-181186

Published: 2023

Journal Articles

Targeted Protein Degradation for c-MYC Overcomes Therapy Resistance in T-Cell Acute Lymphoblastic Leukemias

Faryal Munir, Shayaun Khazaei, Phoebe H. Calkins, Darah Scruggs, Hideaki Mizuno, Lauren B. Ostermann, Branko Cuglievan, Miriam B. Garcia, Dong Chen, Youzhi Tong, Zhihua Ren, Michael Andreeff, Yuki Nishida

Blood (2023) 142 (Supplement 1): 1447.

https://doi.org/10.1182/blood-2023-187496

Published: 2023

Journal Articles

Mitophagy As a Novel Cell-Protective Mechanism Against Mitochondrial Ferroptosis in Acute Myeloid Leukemia

Hiroki Akiyama, Matthew Tcheng, Priyanka Sharma, Ran Zhao, Lauren B. Ostermann, Samar Yazdani, Arman Moayed, Zdzislaw Szulc, Natalia Oleinik, Po Yee Mak, Vivian Ruvolo, Bing Z. Carter, Besim Ogretmen, Gautam Borthakur, Aaron D. Schimmer, Michael Andreeff, Jo Ishizawa

Blood (2023) 142 (Supplement 1): 2804.

https://doi.org/10.1182/blood-2023-181410

Published: 2023

Journal Articles

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Inhibiting Drp1 Dependent Mitochondrial Fission

Priyanka Sharma, Lauren B. Ostermann, Sujan Piya, Baozhen Ke, Natalia Baran, Anudishi Tyagi, Muharrem Muftuoglu, Mahesh Basyal, Qi Zhang, Joanne Munck, Kim-Hien Dao, Martin Sims, Bing Z. Carter, Venkata Lokesh Battula, Michael Andreeff, Gautam Borthakur

Blood (2023) 142 (Supplement 1): 412.

https://doi.org/10.1182/blood-2023-185700

Published: 2023

Journal Articles

Age-Specific Induction of Mutant p53 Drives Clonal Hematopoiesis in Adult Mice Leading to Acute Myeloid Leukemia

Rasoul Pourebrahim, Shayaun Khazaei, Lauren B. Ostermann, Ran Zhao, Muharrem Muftuoglu, Michael Andreeff

Blood (2023) 142 (Supplement 1): 1382.

https://doi.org/10.1182/blood-2023-186454

Published: 2023

Journal Articles

Stem-Cell Enriched Cellular Hierarchy of TP53 Mutant Acute Myeloid Leukemia Is Vulnerable to Targeted Protein Degradation of c-MYC

Blood (2023) 142 (Supplement 1): 583.

https://doi.org/10.1182/blood-2023-174938

Published: 2023

Journal Articles

Novel Hypomethylating Agent Ntx-301 Exhibits Anti-Leukemia Activity in Venetoclax-Resistant and TP53-Mutant AML

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Andrea Bedoy, Steffen Boettcher, Lauren B. Ostermann, Elizabeth J. Shpall, Michael Andreeff

Blood (2023) 142 (Supplement 1): 4158.

https://doi.org/10.1182/blood-2023-180051

Published: 2023

Journal Articles

Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells

Blood (2023) 142 (12): 1056–1070.

https://doi.org/10.1182/blood.2022019047

Published: 2023

Includes: Supplemental data

Journal Articles

Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia

Rasoul Pourebrahim, Rafael Heinz Montoya, Edward Ayoub, Hiroki Akiyama, Natalia Baran, Tom Lesluyes, Lauren B Ostermann, Bin Liu, Jo Ishizawa, Joseph D. Khoury, Marina Konopleva, Peter Van Loo, Michael Andreeff

Blood (2022) 140 (Supplement 1): 5876–5878.

https://doi.org/10.1182/blood-2022-167859

Published: 2022

Journal Articles

Traceable Mouse Models for Tracking p53-Mutant Subclones in Acute Myeloid Leukemia

Rasoul Pourebrahim, Rafael Heinz Montoya, Lauren B Ostermann, Michael Andreeff

Blood (2022) 140 (Supplement 1): 2964–2965.

https://doi.org/10.1182/blood-2022-167905

Published: 2022

Journal Articles

Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Yuki Nishida, Naveen Pemmaraju, Steffen Boettcher, Elizabeth J Shpall, Gabriela Chiosis, Georgios Karras, Barbara Wallner, Robert A Morgan, Michael Andreeff

Blood (2022) 140 (Supplement 1): 5930–5931.

https://doi.org/10.1182/blood-2022-158547

Published: 2022

Journal Articles

Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3 -ITD/-TKD Mutant AML in a PDX Model

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Duncan Mak, Boazhen Ke, Peter Ordentlich, Gerard M. McGeehan, Michael Andreeff

Blood (2022) 140 (Supplement 1): 3063–3064.

https://doi.org/10.1182/blood-2022-158570

Published: 2022

Journal Articles

Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia

Hiroki Akiyama, Ran Zhao, Yuki Nishida, Natalia Baran, Ziyi Li, Lauren B Ostermann, Po Yee Mak, Edward Ayoub, Sujan Piya, Bing Z Carter, Michael Andreeff, Jo Ishizawa

Blood (2022) 140 (Supplement 1): 8785–8786.

https://doi.org/10.1182/blood-2022-162354

Published: 2022

Journal Articles

Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Steffen Boettcher, Yuki Nishida, Edward Ayoub, Vivian Ruvolo, Elias J. Jabbour, Paul Hughes, PK Morrow, Michael Andreeff

Blood (2021) 138 (Supplement 1): 2239.

https://doi.org/10.1182/blood-2021-148014

Published: 2021

NARROW

Molecular Interactions between Mitochondrial Ferroptosis and Apoptosis Pathways in Acute Myeloid Leukemia

Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells

Reactivation of p53 in TP53 -Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms

Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors

Calibrated Release IL15 Bivalent CD33 and/or FLT3 and NOT Emcn Logic Gated Gene Circuit CAR-NK Cell Therapy (SENTI-202) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models

Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2

Targeted Protein Degradation for c-MYC Overcomes Therapy Resistance in T-Cell Acute Lymphoblastic Leukemias

Mitophagy As a Novel Cell-Protective Mechanism Against Mitochondrial Ferroptosis in Acute Myeloid Leukemia

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Inhibiting Drp1 Dependent Mitochondrial Fission

Age-Specific Induction of Mutant p53 Drives Clonal Hematopoiesis in Adult Mice Leading to Acute Myeloid Leukemia

Stem-Cell Enriched Cellular Hierarchy of TP53 Mutant Acute Myeloid Leukemia Is Vulnerable to Targeted Protein Degradation of c-MYC

Novel Hypomethylating Agent Ntx-301 Exhibits Anti-Leukemia Activity in Venetoclax-Resistant and TP53-Mutant AML

Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells

Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia

Traceable Mouse Models for Tracking p53-Mutant Subclones in Acute Myeloid Leukemia

Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML

Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3 -ITD/-TKD Mutant AML in a PDX Model

Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia

Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only